Science journalist
Elie Dolgin, PhD, is a freelance science journalist who specializes in biomedical research and drug discovery.
Elie Dolgin is a science journalist who splits his time between rural Vermont and urban Massachusetts. He holds a bachelor's degree in biology from McGill University and a PhD in evolutionary genetics from the University of Edinburgh. A former news editor at STAT, Nature Medicine and The Scientist, Elie has also written for publications including the New York Times, Newsweek and Science magazine.
His 2021 feature article for Nature, "The tangled history of mRNA vaccines," gained significant recognition and was referenced widely in the scientific literature, in national newspaper stories and by award selection committees.
In The Media
Recent Projects
Pulses of light and sound seem to have beneficial effects. But some argue it is too soon to market experimental devices.
The medication is the first in decades to have a different mode of action than do current drugs, achieving better symptom relief with fewer side effects.
Pain is defined subjectively, but an objective measure of the experience promises to transform its management.
Joining a drug candidate to a protein that malignant cells naturally take up allowed one firm to come up with a potent anti-cancer therapy.
The tumor-seeking radiopharmaceuticals are charting a new course in oncology, with promise for targeted treatments with fewer side effects.
Moderna employees build RNA vaccines tailored to an individual’s tumour at a facility in Norwood, Massachusetts.
Time spent outdoors is the best defence against rising rates of short-sightedness, but scientists are searching for other ways to reverse the troubling trend.
The new fiber-optic probe could transform aneurysm and brain clot treatments
Drug trial results show that vaccines aren't the only use for the mRNA technology behind the most widely used COVID-19 jabs.